CZ303944B6 - Pouzití 4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-((4-pyridin-3-yl)pyrimidin-2-ylamino)fenyl)benzamidu pri lécbe gastrointestinálních stromálních tumoru - Google Patents

Pouzití 4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-((4-pyridin-3-yl)pyrimidin-2-ylamino)fenyl)benzamidu pri lécbe gastrointestinálních stromálních tumoru Download PDF

Info

Publication number
CZ303944B6
CZ303944B6 CZ20031152A CZ20031152A CZ303944B6 CZ 303944 B6 CZ303944 B6 CZ 303944B6 CZ 20031152 A CZ20031152 A CZ 20031152A CZ 20031152 A CZ20031152 A CZ 20031152A CZ 303944 B6 CZ303944 B6 CZ 303944B6
Authority
CZ
Czechia
Prior art keywords
formula
treatment
methyl
benzamide
phenyl
Prior art date
Application number
CZ20031152A
Other languages
Czech (cs)
English (en)
Other versions
CZ20031152A3 (en
Inventor
Buchdunger@Elisabeth
Capdeville@Renaud
Daniel Demetri@George
Dimitrijevic@Sasa
Jay Druker@Brian
A. Fletcher@Jonathan
Joensuu@Heikki
Leta Silberman@Sandra
Tuveson@David
C. Heinrich@Michael
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22920224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ303944(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CZ20031152A3 publication Critical patent/CZ20031152A3/cs
Publication of CZ303944B6 publication Critical patent/CZ303944B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)
CZ20031152A 2000-10-27 2001-10-26 Pouzití 4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-((4-pyridin-3-yl)pyrimidin-2-ylamino)fenyl)benzamidu pri lécbe gastrointestinálních stromálních tumoru CZ303944B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24381000P 2000-10-27 2000-10-27

Publications (2)

Publication Number Publication Date
CZ20031152A3 CZ20031152A3 (en) 2004-04-14
CZ303944B6 true CZ303944B6 (cs) 2013-07-10

Family

ID=22920224

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20031152A CZ303944B6 (cs) 2000-10-27 2001-10-26 Pouzití 4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-((4-pyridin-3-yl)pyrimidin-2-ylamino)fenyl)benzamidu pri lécbe gastrointestinálních stromálních tumoru

Country Status (25)

Country Link
US (1) US6958335B2 (enExample)
EP (1) EP1332137B1 (enExample)
JP (1) JP4386635B2 (enExample)
KR (1) KR100885129B1 (enExample)
CN (1) CN1276754C (enExample)
AT (1) ATE321556T1 (enExample)
AU (2) AU1826202A (enExample)
BR (1) BRPI0114870B8 (enExample)
CA (1) CA2424470C (enExample)
CY (1) CY1105055T1 (enExample)
CZ (1) CZ303944B6 (enExample)
DE (1) DE60118430T2 (enExample)
DK (1) DK1332137T3 (enExample)
ES (1) ES2260317T3 (enExample)
HU (1) HU229106B1 (enExample)
IL (2) IL155029A0 (enExample)
MX (1) MXPA03003703A (enExample)
NO (1) NO324948B1 (enExample)
NZ (1) NZ525254A (enExample)
PL (1) PL209733B1 (enExample)
PT (1) PT1332137E (enExample)
RU (1) RU2301066C2 (enExample)
SK (1) SK287335B6 (enExample)
WO (1) WO2002034727A2 (enExample)
ZA (1) ZA200302155B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CA2444867C (en) * 2001-05-16 2010-08-17 Novartis Ag Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
ES2274075T3 (es) * 2001-06-29 2007-05-16 Ab Science Utilizacion de inhibidores de c-kit para tratar enfermedades inflamatorias intestinales (eii).
CA2452366A1 (en) * 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
DK1401415T3 (da) * 2001-06-29 2006-10-16 Ab Science Anvendelse af N-phenyl-2-pyrimidinamin-derivater til behandling af inflammatoriske sygdomme
ES2274993T3 (es) * 2001-06-29 2007-06-01 Ab Science Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
CA2452368A1 (en) * 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
ATE401078T1 (de) * 2001-09-20 2008-08-15 Ab Science Die verwendung von c-kithemmern zur förderung des haarwuchses
ATE404202T1 (de) * 2001-09-20 2008-08-15 Ab Science Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
ES2269994T3 (es) * 2002-02-27 2007-04-01 Ab Science Utilizacion de inhibidores de la tirosina quinasa, para el tratamiento de los trastornos del snc.
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
MXPA06003056A (es) * 2003-09-19 2006-05-31 Novartis Ag Tratamiento de tumores estromales gastrointestinales con imatinib y midostaurin.
US20100210596A1 (en) * 2006-02-01 2010-08-19 Bluestone Jeffrey A Use of aminopyrimidine compounds in the treatment of immune disorders
EP2061772A4 (en) * 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
AU2007296743B2 (en) * 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US8530492B2 (en) 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
EP2680850B1 (en) 2011-03-04 2018-05-23 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US20160015708A1 (en) 2012-02-21 2016-01-21 Ranbaxy Laboratories Limited Stable dosage forms of imatinib mesylate
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
BR112015001838B1 (pt) 2012-07-27 2022-10-25 Izumi Technology, Llc Composição de inibidor de efluxo
AU2014296032A1 (en) 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
WO2019016673A2 (en) 2017-07-20 2019-01-24 Kashiv Pharma Llc STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB
WO2019152711A1 (en) 2018-01-31 2019-08-08 Diciphera Pharmaceuticals Llc. Combination therapy for the treatment of gastrointestinal stromal tumors
KR102708050B1 (ko) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. 비만 세포증의 치료를 위한 병용 요법
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANINE CANCERS
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
CA3150433A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
KR102535840B1 (ko) 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (de) * 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidinderivate und Verfahren zu ihrer Herstellung
WO1999003854A1 (en) * 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1528449A1 (ru) * 1985-06-05 1989-12-15 Центральный институт усовершенствования врачей Способ релаксации илеоцекального отдела кишечника
CA2342222A1 (en) * 1998-08-31 2000-03-09 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (de) * 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidinderivate und Verfahren zu ihrer Herstellung
WO1999003854A1 (en) * 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use

Also Published As

Publication number Publication date
IL155029A (en) 2009-09-22
KR100885129B1 (ko) 2009-02-23
CA2424470A1 (en) 2002-05-02
JP2004512328A (ja) 2004-04-22
BR0114870A (pt) 2004-02-17
EP1332137A2 (en) 2003-08-06
PL362148A1 (en) 2004-10-18
CY1105055T1 (el) 2010-03-03
HK1058193A1 (en) 2004-05-07
ZA200302155B (en) 2004-04-22
PT1332137E (pt) 2006-07-31
US6958335B2 (en) 2005-10-25
HU229106B1 (en) 2013-07-29
HUP0301512A2 (hu) 2003-11-28
NO20031833D0 (no) 2003-04-24
WO2002034727A3 (en) 2003-03-27
CN1276754C (zh) 2006-09-27
CA2424470C (en) 2009-06-09
CZ20031152A3 (en) 2004-04-14
ES2260317T3 (es) 2006-11-01
CN1622808A (zh) 2005-06-01
NO20031833L (no) 2003-04-24
AU2002218262B2 (en) 2005-09-29
EP1332137B1 (en) 2006-03-29
SK5182003A3 (en) 2004-02-03
AU1826202A (en) 2002-05-06
ATE321556T1 (de) 2006-04-15
BRPI0114870B8 (pt) 2021-05-25
NO324948B1 (no) 2008-01-07
US20040023976A1 (en) 2004-02-05
WO2002034727A2 (en) 2002-05-02
DE60118430D1 (de) 2006-05-18
BRPI0114870B1 (pt) 2020-06-16
NZ525254A (en) 2006-02-24
RU2301066C2 (ru) 2007-06-20
PL209733B1 (pl) 2011-10-31
KR20030051656A (ko) 2003-06-25
SK287335B6 (sk) 2010-07-07
DE60118430T2 (de) 2006-10-26
DK1332137T3 (da) 2006-07-17
JP4386635B2 (ja) 2009-12-16
MXPA03003703A (es) 2005-01-25
IL155029A0 (en) 2003-10-31

Similar Documents

Publication Publication Date Title
CZ303944B6 (cs) Pouzití 4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-((4-pyridin-3-yl)pyrimidin-2-ylamino)fenyl)benzamidu pri lécbe gastrointestinálních stromálních tumoru
AU2002218262A1 (en) Treatment of gastrointestinal stromal tumors
WO2008109057A1 (en) Organic compounds and their uses
JP2025106456A (ja) 胆管癌を治療するための方法
TWI866427B (zh) 雌激素受體降解劑之給藥方案
ES2934846T3 (es) Inhibidores de CDK para tratamiento de PAH
KR20240006600A (ko) 투약 요법
HK1058193B (en) Treatment of gastrointestinal stromal tumors
TW202539669A (zh) 雌激素受體降解劑之給藥方案
EP1474148A1 (en) Treatment of neuroblastoma
WO2004009088A1 (en) 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer

Legal Events

Date Code Title Description
MK4A Patent expired

Effective date: 20211026